CDK Global has successfully renewed its DMS agreement with Sonic Automotive, securing a key partnership following two ...

The news reinforces CDK's reputation in the DMS business and, presumably, will help the company land more extensions and new ...

RHHBY has strengthened its pipeline with an agreement to acquire Regor's portfolio of next-generation CDK inhibitors for the treatment of breast cancer.

Genentech has acquired Regor Pharmaceuticals’ next-generation CDK inhibitors for breast cancer treatment in a deal worth ...

Meanwhile, the acquisition of AntlerA, which Roche called a leader in Wnt signaling, gives the pharma ownership of a library ...

The contract extension with Sonic is a win for market leader CDK, which faced challenges over the summer after two ...

It hasn’t been the best of years for CDK Global, but it got some good news Monday. Sonic Automotive, one of the nation’s ...

CDK, the leading automotive retail software provider, today announced the extension of its agreement with Sonic Automotive, ...

Roche is spending $850 million upfront to buy Regor Pharmaceuticals’ suite of next-generation CDK inhibitors as it doubles ...

A federal judge in Illinois has granted preliminary approval to a settlement in which CDK Global agrees to pay $100 million ...

Cambridge, Massachusetts-based biotech Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors for the ...

Regor Pharmaceuticals USA has entered into a definitive purchase agreement, under which Genentech, a member of the Roche Group, will ...